Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Oct. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0661218/Atherosclerosis-or-Coronary-Artery-Disease-Therapeutics-CAD---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. The report identifies the key trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Atherosclerosis or Coronary Artery Disease (CAD) sector. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData's team of industry experts.
GlobalData analysis shows that the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market stood at $12.0 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 3.5% to reach $14.2 billion in 2010. GlobalData forecasts that the global CAD therapeutics market will grow at a CAGR of 1.0% over the next eight years to reach $15,432.2m by 2018. The Atherosclerosis or Coronary Artery Disease (CAD) therapeutics markert is comprised of statins, angiotensin-converting enzyme (ACE) inhibitors, beta blokers (BB), antiplatlets, calcium channel blockers (CCBs) and nitrates. The growth in CAD therapeutics market is mainly driven by increased prevalence, sedentary lifestyle obesity, hypertension, dyslipidemia, particularly reduction in high density cholesterol (HDL-C) and high cholesterol diet. The mentioned causative factors are responsible for increasing number of patients with CAD or likely develop in future. With the launch of first-in-class pipeline molecules such as Darapladib, Dalcetrapib (RG1658), Mipomersen (ISIS 301012), Vorapaxar (SCH 530348), Canakinumab (ACZ885), Varespladib (A 002), Aliskiren, Generx, Xarelto (rivaroxaban) and Anacetrapib (MK0859) these are expected to get launched in forecasting period. New entrants in the CAD therapeutics market have shown increased efficacy and safety profiles along with reduction of CHD risk factors.
The treatment options for CAD patients are drugs such as Lipitor (atorvastatin calicium), Crestor (rosuvastatin calcium), Angiomax (bivalirudin), Plavix (clopidogrel bisulfate), Effient (prasugrel), Norvasc (amlodipine) and Altace (ramipril). The impending patent expiry of Lipitor in November 2011; Plavix, Effient and Angiomax in 2012 and Crestor in 2016 means patients will have access to treatment at much lower prices reflecting brand erosion of these drugs. The patent expiries of Lipitor, Crestor, Plavix and Effient will show an impact in the CAD theapeutics market during the forecast period.
Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).
Scope
The report provides information on the key drivers and challenges of the Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan); Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. The pipeline for Atherosclerosis or Coronary Artery Disease (CAD) has novel therapies with mechanis of action such as CETP inhibitors, Interleukin-1? inhibitor, FXR Inhibitors, P2Y12ADP receptor antagonist, SREBP2 activator and p38 kinase inhibitors.
- Analysis of the current and future competition in the seven key countries' Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market. The key market players for Atherosclerosis or Coronary Artery Disease (CAD) in future will be GlaxoSmithKline plc, Merck & Co., Inc, F. Hoffmann-La Roche Ltd, Isis Pharmaceuticals, Inc, Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company and Cardium Therapeutics
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and the implications for the Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market.
- Analysis of key recent licensing and partnership agreements in the Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Atherosclerosis or Coronary Artery Disease (CAD) therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios, and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Atherosclerosis or Coronary Artery Disease (CAD) market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 8
2 Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Executive Summary 10
2.1 The CAD Therapeutics Market is Competitive and Expected to Grow Due to Expected Lauch of New Molecules During the Forecast Period 10
2.2 The Current Competition in the CAD Therapeutics Market Is Strong 11
2.3 Strong Pipeline Would Drive the Atherosclerosis or CAD Therapeutics Market During the Forecast Period 12
2.4 Significant Unmet Need Provides Scope for New Entrants 12
3 Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics – Introduction 14
3.1 Overview 14
3.2 Type of Atherosclerosis 14
3.3 Epidemiology 15
3.4 Etiology 16
3.4.1 Cells and Lipids 16
3.4.2 ECM (Extracellular Matrix) 16
3.4.3 Endothelial injury as the mechanism of atherosclerosis 16
3.4.4 Role of low-density lipoprotein-oxidative stress 17
3.4.5 Risk factors 17
3.5 Symptoms 19
3.6 Diagnosis 21
3.7 Pathophysiology 22
3.8 Treatment and Management Pattern 23
3.8.1 HMG-CoA Reductase Inhibitors 23
3.8.2 ACE Inhibitors 24
3.8.3 Beta Blockers 24
3.8.4 Omega-3 Fatty Acids 24
3.8.5 Aldosterone Antagonists 24
3.8.6 Calcium Channel Blockers 24
3.8.7 Nicotinic Acid Derivatives 24
3.8.8 Fibric Acid Derivatives 24
3.8.9 Platelet Aggregation Inhibitors 24
4 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Market Characterization 28
4.1 Coronary Artery Disease (CAD) Therapeutics Market Size (2005-2010) – Global 28
4.2 Atherosclerosis or Coronary artery disease (CAD) Therapeutics Market Forecast (2010-2018) – Global 29
4.3 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market – The US (2005-2010) 31
4.4 Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market Forecast – The US (2010-2018) 33
4.5 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market – France (2005-2010) 34
4.6 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market Forecast – France (2010-2018) 36
4.7 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market – Germany (2005-2010) 37
4.8 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market Forecast - Germany (2010-2018) 39
4.9 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market – Italy (2005-2010) 40
4.10 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market Forecast – Italy (2010-2018) 42
4.11 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market – Spain (2005-2010) 44
4.12 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market Forecast – Spain (2010-2018) 46
4.13 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market – The UK (2005-2010) 47
4.14 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market Forecast – The UK (2010-2018) 49
4.15 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market - Japan (2005-2010) 50
4.16 Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market Forecast – Japan (2010-2018) 52
4.17 Drivers and Barriers for the Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market 54
4.17.1 Atherosclerosis or Coronary Artery Disease (CAD)_Therapeutics Market Drivers 54
4.17.2 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics Market Barriers 54
4.18 Opportunity and Unmet Need 55
4.19 Key Takeaway 57
5 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Competitive Assessment 58
5.1 Overview 58
5.2 Strategic Competitor Assessment 58
5.3 Product Profile for the Major Market Products in the Coronary Atherosclerosis or Coronary Artery Disease (CAD) 59
5.3.1 Lipitor (atorvastatin calcium) 59
5.3.2 Crestor (rosuvastatin calcium) 61
5.3.3 Plavix (clopidogrel bisulfate) 63
5.3.4 Effient (prasugrel) 64
5.3.5 Altace (ramipril) 67
5.3.6 Norvasc (amlodipine) 69
5.3.7 Niaspan (nicotinic acid) 71
5.4 Key Takeaway 73
6 Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Pipeline Assessment 74
6.1 Overview 74
6.2 Strategic Pipeline Assessment 74
6.3 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics Market – Pipeline Assessment by Phase of Development 75
6.3.1 Coronary Artery Disease (CAD) Therapeutics – Phase III Pipeline 75
6.3.2 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Phase II Pipeline 75
6.3.3 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Phase I Clinical Pipeline 76
6.3.4 Coronary Artery Disease (CAD) Therapeutics – Preclinical Pipeline 77
6.3.5 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Discovery Pipeline 77
6.4 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Pipeline by Mechanism of Action 78
6.5 Technology Trends Analytical Framework 80
6.6 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics Market – Most Promising Drugs Under Clinical Development 83
6.7 Most Promising Drug Profiles 84
6.7.1 Anacetrapib (MK- 0859) 84
6.7.2 Darapladib 85
6.7.3 Dalcetrapib (RG1658) 87
6.7.4 Mipomersen 88
6.7.5 Varespladib (A-002) 90
6.7.6 MK- 0524B 91
6.7.7 Aleglitazar (RG1439) 93
6.7.8 Vorapaxar 94
6.7.9 Aliskiren 96
6.7.10 Canakinumab (ACZ885) 97
6.7.11 Genrex 98
6.7.12 Cangrelor 99
6.7.13 Otamixaban 100
6.7.14 Xarelto (rivaroxaban) 101
6.8 Key Takeaway 103
7 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Clinical Trials Mapping 104
7.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 104
7.2 Clinical Trials by Phase of Clinical Development 105
7.3 Clinical Trials by Trial Status 106
7.4 Prominent Sponsors 107
7.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials 110
8 Coronary Artery Disease (CAD)Therapeutics – Strategic Assessment 112
8.1 Key Events Impacting the Future Market 112
8.2 Future Market Competition Scenario 113
9 Coronary Artery Disease (CAD)Therapeutics – Future Players 115
9.1 Introduction 115
9.2 Company Profiles 115
9.2.1 GlaxoSmithKline Plc 115
9.2.2 Merck & Co., Inc. 117
9.2.3 F Hoffmann La Roche 119
9.2.4 ISIS Pharmaceuticals 120
9.2.5 Anthera Pharmaceuticals 122
9.2.6 Novartis A G 122
9.2.7 Sanofi 124
9.2.8 Johnson & Johnson 125
9.2.9 Bayer AG 126
9.2.10 Cardium Therapeutics 128
9.2.11 The Medicines Company 130
9.2.12 Tabular Presentation Details of Other Companies in the Pipeline 133
9.2.13 Key Takeaway 140
10 Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Licensing & Partnership Deals 141
11 Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics: Appendix 150
11.1 Market Definitions 150
11.2 Acronyms 150
11.3 Methodology 152
11.3.1 Coverage 153
11.3.2 Secondary Research 153
11.3.3 Forecasting 153
11.3.4 Primary Research 156
11.3.5 Expert Panel Validation 157
11.4 Contact Us 157
11.5 Disclaimer 157
11.6 Bibliography 158
List of Tables
Table 1: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics - Modified AHA Consensus Classification Based on Morphologic Descriptions* 15
Table 2: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics – NCEP ATP III Classification of Cholesterol and Triglyceride Levels 22
Table 3: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics - ATP III LDL-C Goals and Outpoints for Therapeutics Lifestyle Changes and Drug Therapy in Different Risk Categories 25
Table 4: Atherosclerosis or Coronary artery disease (CAD) Therapeutics Market, Global, Revenue ($bn), 2005–2010 29
Table 5: Atherosclerosis or Coronary artery disease (CAD) Therapeutics Market, Global, Forecast ($bn), 2010–2018 31
Table 6: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market, The US, Forecast ($mn), 2005–2010 32
Table 7: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, The US, Forecast ($bn), 2010–2018 34
Table 8: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, France, Revenue ($m), 2005–2010 35
Table 9: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, France, Forecast ($m), 2010–2018 37
Table 10: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Germany, Revenue ($bn), 2005–2010 38
Table 11: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Germany, Forecast ($m), 2010–2018 40
Table 12: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market, Italy, Revenue ($m), 2005–2010 42
Table 13: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Italy, Forecast ($m), 2010–2018 44
Table 14: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Spain, Revenue ($m), 2005–2010 45
Table 15: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Spain, Forecast ($m), 2010–2018 47
Table 16: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, The UK, Revenue ($m), 2005–2010 48
Table 17: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, The UK, Forecast ($m), 2010–2018 50
Table 18: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Japan, Revenue ($m), 2005–2010 52
Table 19: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Japan, Forecast ($m), 2010–2018 53
Table 20: Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics – Phase III Pipeline, 2011 75
Table 21: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Phase I Pipeline, 2011 76
Table 22: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Phase I Pipeline, 2011 77
Table 23: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Preclinical Pipeline, 2011 77
Table 24: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Discovery Pipeline, 2011 78
Table 25: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Most Promising Drugs Under Clinical Development, 2011 83
Table 26: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Clinical Trials by Country, 2011 104
Table 27: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Major Markets – Clinical Trials by Phase, 2011 106
Table 28: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 107
Table 30: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Major Markets, Prominent Sponsors, 2011 109
Table 31: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Companies Participating in Clinical Trials, 2011 110
Table 32: GlaxoSmithKline Pipeline Products 117
Table 33: Merck Pipeline Products 119
Table 34: Pipeline Products 122
Table 35: Anthera Pharmaceuticals Company Pipeline Products 122
Table 36: Novartis A G Company Pipeline Products 124
Table 37: Sanofi – CAD Pipeline Products, 2011 125
Table 38: Johnson and Johnson Company – CAD Pipeline Products, 2011 126
Table 39: Bayer AG – CAD Pipeline Products, 2011 128
Table 40: Cardium Therapeutics, Inc., Product pipeline 2011 130
Table 41: Product pipeline 2011 132
Table 42: Other Companies in Pipeline, CAD Therapeutics, 2011 134
Table 43: CAD Therapeutics, Global, Deals, 2011 141
List of Figures
Figure 1: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics, Global, Revenue and Market Forecast ($bn), 2005–2018 11
Figure 2: Opportunity and Unmet Need in the Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market 13
Figure 3: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics – Endothelial Dysfunction 19
Figure 4: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics – Pathology 27
Figure 5: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market, Global, Revenue ($bn), 2005–2010 29
Figure 6: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market, Global, Forecast ($bn), 2010–2018 30
Figure 7: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market, The US, Revenue ($m), 2005–2010 32
Figure 8: Atheosclerosis or Coronary Artery Disease (CAD) Therapeutics Market, The US, Forecast ($bn), 2010–2018 33
Figure 9: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, France, Revenue ($m), 2005–2010 35
Figure 10: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, France, Forecast ($m), 2010–2018 36
Figure 11: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Germany, Revenue ($bn), 2005–2010 38
Figure 12: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Germany, Forecast ($bn), 2010–2018 39
Figure 13: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Italy, Revenue ($m), 2005–2010 41
Figure 14: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Italy, Forecast ($m), 2010–2018 43
Figure 15: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Spain, Revenue ($m), 2005–2010 45
Figure 16: CAD Therapeutics Market, Spain, Forecast ($m), 2010–2018 46
Figure 17: CAD Therapeutics Market, The UK, Revenue ($m), 2005–2010 48
Figure 18: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, The UK, Forecast ($m), 2010–2018 49
Figure 19: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Japan, Revenue ($m), 2005–2010 51
Figure 20: Atheosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Japan, Forecast ($m), 2010–2018 53
Figure 21: Opportunity and Unmet Need in the Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics Market, 2011 56
Figure 22: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics - Strategic Competitor Assessment, 2011 59
Figure 23: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Clinical Pipeline by Mechanism of Action, 2011 79
Figure 24: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics Market – Pipeline by Phase of Development, 2011 80
Figure 25: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics Market Technology Trends Analytics Framework, 2011 81
Figure 26: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics - Technology Trends Analytics Framework – Description, 2011 82
Figure 27: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics – Clinical Trials by Country, 2011 104
Figure 28: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Major Markets – Clinical Trials by Phase, 2011 105
Figure 29: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Major Markets, Clinical Trials by Development Status, 2011 107
Figure 30: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Overall Sponsors, 2011 108
Table 29: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Major Markets, Overall Sponsors, 2011 108
Figure 31: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Global, Prominent Sponsors (%), 2011 109
Figure 32: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics, Clinical Trials of Top Ten Companies by Phase, 2011 110
Figure 33: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, Drivers and Barriers 2011 112
Figure 34: Implications for Future Market Competition in the Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics Market, 2011 113
Figure 35: Atherosclerosis or Coronary Artery Disease (CAD)Therapeutics Market – Clinical Pipeline by Company, 2011 115
Figure 36: GlobalData Market Forecasting Model 155GlaxoSmithKline Plc
Merck & Co., Inc.
F Hoffmann La Roche
ISIS Pharmaceuticals
Anthera Pharmaceuticals
Novartis A G
Sanofi
Johnson & Johnson
Bayer AG
Cardium Therapeutics
The Medicines Company
To order this report:
Pathology Industry: Atherosclerosis or Coronary Artery Disease Therapeutics (CAD) - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article